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cancer risk: individual participant meta-analysis of the 
worldwide epidemiological evidence
Collaborative Group on Hormonal Factors in Breast Cancer*
Summary
Background Published findings on breast cancer risk associated with different types of menopausal hormone therapy 
(MHT) are inconsistent, with limited information on long-term effects. We bring together the epidemiological 
evidence, published and unpublished, on these associations, and review the relevant randomised evidence.
Methods Principal analyses used individual participant data from all eligible prospective studies that had sought 
information on the type and timing of MHT use; the main analyses are of individuals with complete information on 
this. Studies were identified by searching many formal and informal sources regularly from Jan 1, 1992, to Jan 1, 2018. 
Current users were included up to 5 years (mean 1·4 years) after last-reported MHT use. Logistic regression yielded 
adjusted risk ratios (RRs) comparing particular groups of MHT users versus never users. 
Findings During prospective follow-up, 108 647 postmenopausal women developed breast cancer at mean age 
65 years (SD 7); 55 575 (51%) had used MHT. Among women with complete information, mean MHT duration was 
10 years (SD 6) in current users and 7 years (SD 6) in past users, and mean age was 50 years (SD 5) at menopause 
and 50 years (SD 6) at starting MHT. Every MHT type, except vaginal oestrogens, was associated with excess breast 
cancer risks, which increased steadily with duration of use and were greater for oestrogen-progestagen than oestrogen-
only preparations. Among current users, these excess risks were definite even during years 1–4 (oestrogen-progestagen 
RR 1·60, 95% CI 1·52–1·69; oestrogen-only RR 1·17, 1·10–1·26), and were twice as great during years 5–14 (oestrogen-
progestagen RR 2·08, 2·02–2·15; oestrogen-only RR 1·33, 1·28–1·37). The oestrogen-progestagen risks during years 
5–14 were greater with daily than with less frequent progestagen use (RR 2·30, 2·21–2·40 vs 1·93, 1·84–2·01; 
heterogeneity p<0·0001). For a given preparation, the RRs during years 5–14 of current use were much greater for 
oestrogen-receptor-positive tumours than for oestrogen-receptor-negative tumours, were similar for women starting 
MHT at ages 40–44, 45–49, 50–54, and 55–59 years, and were attenuated by starting after age 60 years or by adiposity 
(with little risk from oestrogen-only MHT in women who were obese). After ceasing MHT, some excess risk persisted 
for more than 10 years; its magnitude depended on the duration of previous use, with little excess following less 
than 1 year of MHT use.
Interpretation If these associations are largely causal, then for women of average weight in developed countries, 
5 years of MHT, starting at age 50 years, would increase breast cancer incidence at ages 50–69 years by about one in 
every 50 users of oestrogen plus daily progestagen preparations; one in every 70 users of oestrogen plus intermittent 
progestagen preparations; and one in every 200 users of oestrogen-only preparations. The corresponding excesses 
from 10 years of MHT would be about twice as great.
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Introduction
A previous meta-analysis of the worldwide evidence 
found that current and recent users of menopausal 
hormone therapy (MHT) were at an increased risk of 
breast cancer, but little information was available about 
the effects of different types of MHT, or about long-term 
risks after MHT use had ceased.1 Since then, much new 
infor mation has become available, including results 
from randomised trials (appendix pp 6–15), generally 
showing greater risks of breast cancer with preparations 
containing both oestrogen and progestagen than with 
preparations containing oestrogen alone, but published 
information on long-term effects of past use has 
remained limited.
MHT has been used mostly in western countries, with 
about 600 million woman-years of use since 1970 (figure 1; 
appendix p 16, 27).2 Use increased rapidly during the 1990s, 
halved abruptly in the early 2000s, and stabilised during 
the 2010s with about 12 million current users. Women 
tend to begin MHT at around the time of the menopause 
and can continue for several years. At these ages, breast 
cancer is the most common malignancy in western 
countries; almost 3% of women are diagnosed with it 
during their 50s (appendix p 17).3 While regulatory bodies 
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in Europe and the USA recommend that MHT be used for 
the shortest time that it is needed,4,5 some clinical 
guidelines recommended less restrictive prescribing.6
Most individual studies were too small to assess 
reliably the long-term breast cancer risk associated 
with just a few years of MHT use. Furthermore, some 
epidemiological evidence remains unpublished, and 
studies completed before the 2000s necessarily had limited 
information about long-term effects of past use.1 Reliable 
assessment of the association between breast cancer risk 
and current and past use of MHT requires review of the 
totality of the worldwide evidence, with careful control of 
potential sources of appreciable bias and confounding. 
Reviews of published data cannot provide this.
The Collaborative Group on Hormonal Factors in 
Breast Cancer has therefore sought to bring together for 
central analysis published and unpublished individual 
participant data from eligible epidemiological studies 
with information on the type and timing of MHT use. 
Bringing these studies together has yielded extremely 
large numbers of cases of breast cancer among women 
who started MHT in their 40s or 50s.
Although relatively few women in the prospective 
studies had started MHT in their 60s, most women in 
the randomised trials of these same preparations were 
older than 60 years when recruited, as these trials were 
designed primarily to evaluate possible protective effects 
against vascular disease (which is less common at 
younger ages). These and other relevant randomised 
trials are reviewed separately here.
Methods
Study identification and data collection
This collaboration began in 1992.1,7–9 Since then, potentially 
eligible epidemiological studies have been sought 
regularly by computer-aided literature searches, manual 
searches of review articles, written com munications, 
and discussions at scientific meetings (appendix p 6). 
Eligible studies, published and unpublished, had sought 
individual information for postmenopausal women on 
Research in context
Evidence before this study
Reliable assessment of the association between menopausal 
hormone therapy (MHT) use and breast cancer requires 
avoidance of appreciable confounding or bias, with important 
features of MHT use (type used, age at first use, duration of use, 
and time since last use) classified similarly. Review of published 
data cannot provide this. We reported in 1997 that current and 
recent users of MHT were at increased risk of breast cancer, 
but little information was then available about different types of 
MHT or about their long-term effects. Systematic searches for 
published and unpublished studies have been done regularly 
since 1992 from collaborators and from review articles and 
reference lists, augmented by periodic searches of MEDLINE and 
PubMed; search terms included combinations of “breast cancer 
risk”, “cohort”, “prospective”, “case-control”, “HT”, “hormonal 
contra*”, “hormone replacement”, “menopaus*”, “reproduc*”, 
“hormon*”, and “HRT’’. The cutoff date for searches was 
Jan 1, 2018. The randomised evidence, also reviewed here, is 
largely for hormone use starting after age 60 years.
Added value of this study
In an individual participant meta-analysis of all eligible 
prospective studies, conclusions can now be based on over 
100 000 postmenopausal women who developed breast cancer. 
Half of these women had used MHT, most starting around the 
time of the menopause at ages 40–59 years. Prospective studies 
avoid the potential biases in retrospective studies, and the large 
number of cases limits the play of chance. All types of MHT, 
except vaginal oestrogens, were associated with increased risks 
of developing breast cancer. The risks were greater for 
oestrogen-progestagen than for oestrogen-only preparations, 
particularly if the progestagen was given daily rather than 
intermittently. The associations with MHT were much stronger 
for oestrogen-receptor-positive tumours than for 
oestrogen-receptor-negative tumours. Among current users, 
there were definite excess risks even during 1–4 years (mean: 
3 years) of MHT use, and progressively greater risks with longer 
use. During 5–14 years of MHT use, the relative risks (RRs) were 
similarly increased if MHT use had started at ages 40–44, 45–49, 
50–54, and 55–59 years; RRs appeared to be attenuated if MHT 
use had started after age 60 years. They were also attenuated by 
adiposity, particularly for oestrogen-only MHT (which had little 
effect in obese women). After MHT use ceased, some excess risk 
of breast cancer persisted for more than a decade, which was 
greater with longer durations of prior MHT use. There was little 
risk following less than 1 year of use.
Implications of all the available evidence
If the associations are largely causal, MHT use in western 
countries has already caused about 1 million breast cancers, out 
of a total of about 20 million since 1990. For women of average 
weight in western countries, 5 years use of oestrogen plus daily 
progestagen MHT, starting at age 50 years, would increase 
20-year breast cancer risks at ages 50–69 years from 
6·3% to 8·3%, an absolute increase of 2·0 per 100 women (one in 
every 50 users). Similarly, 5 years use of oestrogen plus 
intermittent progestagen MHT would increase the 20-year risk 
from 6·3% to 7·7%, an absolute increase of 1·4 per 100 women 
(one in 70 users). Finally, 5 years use of oestrogen-only MHT 
would increase the 20-year risk from 6·3% to 6·8%, an absolute 
increase of 0·5 per 100 women (one in 200 users); this excess 
would be greater in lean women, but in obese women 
oestrogen-only MHT is associated with little excess risk. For 
10 years of use, the 20-year increases in incidence would be about 
twice as great as for 5 years of use.
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the type and timing of MHT use and on body-mass index 
(BMI); and, after 2001, included at least 1000 cases. By 
Jan 1, 2018, 59 eligible studies had been identified and 58 
are included (one retrospective, but no prospective, study 
was unable to provide data on individual participants; 
appendix pp 6–15). Randomised trials involved too few 
cases to be eligible by these criteria, but trials of the main 
MHT preparations are reviewed separately, as are some 
trials of anti-oestrogen drugs (appendix pp 28–30).
Prospective studies were included using a nested case-
control design, with up to four randomly selected 
controls per case of invasive breast cancer matched 
on age, year of birth, and region (appendix p 7). All 
analyses included only postmenopausal women, defined 
as known age at natural menopause (or at bilateral 
oophorectomy) or unknown age at menopause but age 
of at least 55 years (since 90% with a natural menopause 
were postmenopausal by 55 years9) and excluded 
younger women with a hysterectomy but unknown age 
at menopause.
Individual information was sought on socio demo-
graphic, reproductive, and anthropometric factors, and 
on last reported MHT use prior to the date of cancer 
diagnosis for cases and the equivalent date for matched 
controls (hereafter called the index date). Women were 
classified, using as similar definitions as possible 
across studies, by age at first MHT use, duration of use, 
time since last use, and preparation last used. Results 
for the two common MHT categories, oestrogen-only 
and oestrogen-progestagen preparations, are examined 
separately; few women switched between them 
(appendix p 7).
In prospective studies, information on whether women 
had been using MHT was necessarily recorded some 
time before the index date. Some never users or past 
users might have started after information was last 
recorded, but this would be uncommon, as the average 
age at last reported non-use was 63 years, and few women 
start MHT after age 60 years (appendix p 8). Analyses 
therefore assumed that never users would not start and 
past users would not restart (and, for past users, the time 
since last use was increased by 1 year annually until the 
index date).
Conversely, women who last (before the index date) 
reported that they were using MHT might have stopped 
before the index date. They were included as current 
users only if the index date was less than 5 years after 
the last report. Breast cancers that arose within this 
period did so after mean 1·4 years (SD 1·4). Based on 
typical annual continuation rates, an estimated 1·1 years 
of additional use would have accrued among them, far 
less than the average of 8·9 years (SD 6·5) up to the last 
reported use. In current users, duration of use was the 
last-reported duration plus the estimated small 
additional duration up to the index date (appendix p 8). 
About 90% of current users at last report would still 
have been users 1 year before the index date. Sensitivity 
analyses explored other cutoffs and other assumptions 
about MHT continuation (appendix pp 20, 42–44).
Breast cancers were classified, where possible, as 
oestrogen-receptor-positive or oestrogen-receptor-negative 
(ER+ or ER–); as ductal or lobular; and as localised to the 
breast or not (appendix p 8).
Statistical methods
A draft protocol was circulated to collaborators and 
preliminary results were discussed at a meeting of 
investigators in 2011 and, after additional data collection 
and analyses, by correspondence with them in 2017 and 
2018. During this collaborative process, the analysis 
plans evolved.
Conditional logistic regression models comparing 
particular groups of MHT users with never users yielded 
odds ratios (equivalent to incidence rate ratios), which are 
described as relative risks (RRs). To ensure that women in 
one study were compared directly only with similar 
women in the same study, all analyses were routinely 
stratified by study, centre within study, BMI, and fine 
divisions of age at index date, and adjusted for alcohol 
consumption, family history of breast cancer, parity, and 
age at first birth (appendix p 9). To preserve the total 
number analysed, for each such variable unknowns were 
assigned to a separate group. Sensitivity analyses restricted 
analyses to women with complete information for all 
adjustment variables or examined the effect of adjusting 
for additional factors. Separate analyses of the prospective 
and of the retrospective studies were performed.
Age at menopause, an important determinant of breast 
cancer risk9 (and of age at first MHT use), was unknown 
Figure 1: Estimated number of current MHT users in western countries in the 50 years since 1970, and the 
distribution of the dates of diagnosis of breast cancer in the retrospective and the prospective studies
Vertical lines give median dates of diagnosis, and horizontal lines give IQRs. MHT=menopausal hormone therapy.
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for about half the cases, but was known for sufficient 
numbers to estimate with negligible random error any 
differences between groups in mean age at menopause 
(appendix p 9). As breast cancer incidence rates in never 
users increase by a factor of 1·029 per year older at 
menopause,9 any such differences were allowed for not 
by regression but by increasing or decreasing the RR of 
breast cancer in each group by a factor of 1·029 for every 
year of difference in mean age at menopause between 
that group and the corresponding group of never users.
To help assess the clinical relevance of the RRs, they 
were combined with the 2015 age-specific breast cancer 
rates in England, which are typical of many western 
countries,3 to describe the absolute breast-cancer risks at 
ages 50–69 years that would, in the absence of other causes 
of death, be associated with starting various types of MHT 
at age 50 years and continuing for 5 years or for 10 years 
before stopping. Stata (version 15.0) was used for analyses. 
Role of the funding source
The funders of the study had no role in study design, 
data analysis, data collection, data interpretation, 
manuscript preparation, or decision to publish. The 
writing committee had full access to all the data in the 
study and had final responsibility for the decision to 
submit for publication.
Results
Anonymised information on individual participants was 
obtained from 58 studies (appendix pp 10, 11), including 
143 887 postmenopausal women with invasive breast 
cancer (cases) and 424 972 without breast cancer 
(controls). The 24 prospective studies contributed three-
quarters  (108 647) of the cases, diagnosed in median 
year 2005 (IQR 2000–09) at mean age 65 years (SD 7); 
55 575 (51%) had ever used MHT. The 34 retrospective 
studies contributed a quarter (35 240) of the cases, 
Figure 2: Type and timing of MHT use in current users and past users
(A) All current and past users. (B) Past users only, by time since last use of MHT. Fully adjusted relative risks for current versus never users by years of current use, and 
for past users versus never users by years of use and time since cessation of use (prospective studies). MHT=menopausal hormone therapy.
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diagnosed in median year 1995 (IQR 1992–98); 
15 642 (44%) had ever used MHT (figure 1).
Overall, breast cancer risk was greater in MHT ever 
users than never users (appendix p 31). Since the aim is to 
assess risks associated with specific types of MHT in 
relation to the timing of use, further analyses are restricted 
to 128 435 cases, three-quarters (95 717) in prospective 
studies, and 366 965 controls with complete information 
on the type last used, duration of use, and time since last 
use. With this restriction (appendix p 32) or without it 
(appendix p 31), the study-specific RRs for ever users 
versus never users of MHT differed significantly between 
retrospective and prospective studies, as did the RRs for 
current users versus never users (appendix p 33). This 
difference was largely due to lower RRs in North American 
retrospective studies. The RRs for a particular duration of 
use of a particular type of MHT were about one fifth lower 
in the aggregated retrospective than in the aggregated pro-
spective studies (appendix p 19, 34). Given that some 
MHT users in retrospective studies might have been more 
willing than non-users to participate as controls, or that 
there may have been differential recall of use between 
cases and controls, the main analyses include only the 
prospective studies, but corresponding analyses for 
the retrospective studies are in the appendix (pp 50–55). 
As the prospective studies include three-quarters of the 
cases, they would have dominated the overall evidence if 
both study types had been combined.
Among women who developed breast cancer in the 
prospective studies, mean age at menopause was 50 years 
(SD 5), mean age at first MHT use was 50 years (SD 6), 
and mean duration of MHT use was 10 years (SD 6) 
in current users and 7 years (SD 6) in past users. 
Hysterectomy largely determined MHT type; the 
proportions of women reported to have had the procedure 
were 2710 (7%) of 37 951 for oestrogen-progestagen users, 
but 31 187 (84%) of 37 213 for oestrogen-only users.
RRs were consistently greater for oestrogen-
progestagen than oestrogen-only preparations, were 
greater in current than in past users, and (in both 
current and past users) increased steadily with duration 
of use (figure 2). For each MHT type, there was a 
significant excess risk even during years 1–4 (mean: 
year 3) of current use: the RRs were 1·60 (95% CI 
1·52–1·69) for oestrogen-progestagen and 1·17 
(1·10–1·26) for oestrogen-only MHT. During years 5–14 
(mean: year 9) current use the RRs were 2·08 (2·02–2·15) 
for oestrogen-progestagen and 1·33 (1·28–1·37) for 
oestrogen-only MHT. In past users, excess duration-
dependent risks persisted for more than a decade after 
stopping MHT use. There is little information about 
breast cancer risk associated with past use that had 
ceased more than 15 years previously.
Few women had started MHT at ages 30–39 years, but 
among those who were still current users 15 years later, 
there were significant risks with oestrogen-progestagen 
and oestrogen-only preparations (appendix p 40). Sub-
stantial numbers of women, however, had started MHT 
in each of the age groups 40–44, 45–49, 50–54, and 
55–59 years, and for each group the RRs were similar 
(figure 3; appendix pp 35–39). Few women had started 
MHT at ages 60–69 years, and their excess risks during 
years 5–14 of current use were significant for oestrogen-
progestagen (RR 1·75, 95% CI 1·48–2·06) but not for 
oestrogen-only MHT (RR 1·08, 0·90–1·31, based on only 
135 exposed cases). For comparability, the RRs in figure 3 
and in subsequent figures are based on cases arising 
during years 5–14 of MHT use (which includes most 
cases in current users).
Sensitivity analyses left the main findings largely 
unchanged (appendix pp 20, 21, 43, 44). The RRs were 
little altered by additional adjustment for ethnicity, 
education, age at menarche, height, and oral contra-
eptive use, restriction to women with data on all 
adjustment variables, variation of the 5–year cutoff, 
exclusion of the largest or the smaller studies, or 
exclusion of women with an index date of less than 
1 year after the last report. Failure to account for any 
Figure 3: Age at first use: relative risks during years 5–14 of current MHT use
Fully adjusted relative risks for current versus never users during years 5–14 of current use, subdivided by age at first use of MHT, giving in each subgroup a mean age at 
menopause and mean duration of MHT use in cases (prospective studies). Tests for trend in RR with age of start of MHT use (χ², 1 degree of freedom): oestrogen-only 
MHT 4·04, p=0·044; oestrogen-progestagen MHT 6·44, p=0·011. MHT=menopausal hormone therapy.
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additional use between last-recorded use and cancer 
diagnosis would, however, have increased duration-
specific RRs, especially for less than 1 year MHT use.
Figure 4 (and appendix pp 22, 23) show breast cancer 
RRs during years 5–14 (mean: year 9) of current use 
according to the main constituents, doses, and modes 
of delivery of the last-used MHT. For oestrogen-
only preparations, there was no heterogeneity of risk 
between equine oestro gen and oestradiol, or between 
oral admini stration and transdermal. By contrast, there 
appeared to be little risk for topical vaginal oestrogens 
(RR 1·09, 0·97–1·23; p=0·15).
During years 5–14 of use of an oestrogen-progestagen 
combination, the RR was greater for oestrogen plus 
daily progestagen than for oestrogen plus intermittent 
progestagen (which usually involved 10–14 days of 
progestagen per month); RR 2·30 (2·21–2·40) and 
RR 1·93 (1·84–2·01), respectively, heterogeneity 
p<0·0001. In general, the RR did not differ substantially 
by the progestagenic constituent of the combinations, 
including rarely used hormones, such as micronised 
[natural] progesterone (RR 2·05, 1·38–3·56), although 
the RR appeared to be somewhat lower for oestrogen 
plus dydrogesterone (appendix p 45). The RR was 
significantly increased during years 5–14 of progestagen-
only MHT (1·39, 1·11–1·75; p=0·0055) and of tibolone 
(1·57, 1·43–1·72; p<0·0001).
Most studies provided data on tumour characteristics. 
RRs in current users during years 5–14 were substantially 
greater for ER+ than ER– tumours and for lobular than 
ductal tumours, but were similar for localised tumours 
and tumours that had spread beyond the breast (figure 5). 
The appendix (pp 46–47) gives further results by ER 
status.
The RRs during years 5–14 of MHT use varied little  with 
any personal characteristics except BMI (appendix p 49). 
Figure 6 shows the absolute breast cancer incidence rates 
per decade in the age range 55–64 years among never 
users and among current users during years 5–14 of MHT 
use. Risk increased with increasing BMI among never 
users (an association that did not weaken with age, 
appendix p 26), but not among current users. Hence, the 
absolute and relative excess risks associated with MHT 
use were greater for lean women than for obese women. 
For oestrogen-only MHT, the RRs comparing current 
users versus never users in the same BMI category 
were 1·52 (1·45–1·60) for lean, 1·26 (1·19–1·34) for 
overweight, and 1·10 (1·02–1·20) for obese women. For 
Figure 5: Tumour characteristics: relative risks during years 5–14 of current use
Fully adjusted relative risks for current versus never users during years 5–14 (mean: year 9) of use. MHT=menopausal hormone therapy.
Oestrogen-receptor status
ER positive
ER negative
Tumour histology
Lobular
Ductal
Tumour spread
Localised to the breast
Spread beyond the breast
28 498/2330/4491
7059/514/701
3775/466/880
23 644/2622/4247
11 789/1392/2450
8558/857/1387
Number of cases
(never/oestrogen only/
oestrogen and progestagen)
1·45 (1·38–1·53)
1·25 (1·13–1·38)
1·58 (1·43–1·75)
1·25 (1·20–1·31)
1·31 (1·23–1·39)
1·35 (1·25–1·46)
Relative risk (95% CI)
during years 5–14 of 
MHT use
Oestrogen only Oestrogen and 
progestagen
2·44 (2·35–2·54)
1·42 (1·30–1·55)
2·72 (2·51–2·95)
1·89 (1·82–1·97)
2·07 (1·97–2·17)
1·89 (1·78–2·02)
Relative risk (95% CI)
during years 5–14 of 
MHT use
3·02·01·0
Relative risk (95% CI)
3·02·01·0
Relative risk (95% CI)
Figure 4: Main types of MHT: relative risks during years 5–14 of current use
Fully adjusted relative risks for current versus never users during years 5–14 (mean: year 9) of use. MHT=menopausal 
hormone therapy. Appendix p 45 gives results for uncommon constituents.
All oestrogen-only preparations
By constituent
Equine oestrogen
Oestradiol
By mode of administration
Oral
Transdermal
All oestrogen-progestagen preparations 
By progestagenic constituent
(Levo)norgestrel
Norethisterone acetate
Medroxyprogesterone acetate
By frequency of addition of progestagen
Daily
Intermittent
Vaginal oestrogen
Progestagen only
Tibolone
4869
1910
1563
3633
919
8318
1735
2642
2012
3948
3467
437
112
680
Number 
of cases
Relative risk (95% CI)
during years 5–14 of
MHT use
1·33 (1·28–1·38)
1·32 (1·25–1·39)
1·38 (1·30–1·46)
1·33 (1·27–1·38)
1·35 (1·25–1·46)
2·08 (2·02–2·15)
2·12 (1·99–2·25)
2·20 (2·09–2·32)
2·07 (1·96–2·19)
2·30 (2·21–2·40)
1·93 (1·84–2·01)
1·09 (0·97–1·23)
1·39 (1·11–1·75)
1·57 (1·43–1·72)
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Relative risk (95% CI)
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oestrogen-progestagen MHT, the RRs were 2·36 
(2·28–2·45) for lean, 1·92 (1·82–2·02) for overweight, and 
1·65 (1·52–1·79) for obese women. Among never users, 
the incidence of ER– disease was low and little related to 
BMI, but the incidence of ER+ disease increased with 
BMI. Hence, ER+ disease accounted for almost all of the 
association of breast cancer risk with BMI in never users 
and of the MHT-associated excess risk in users (figure 6; 
appendix p 48).
To estimate the absolute risks of breast cancer by age 
70 years that would be associated with starting various 
types of MHT at age 50 years and continuing for 5 years 
or for 10 years, we combined prospective study RRs for 
women who began any oestrogen-progestagen MHT at 
ages 45–54 years (appendix p 41) with estimates of the 
breast cancer incidence rates at ages 50–69 years among 
never users of average weight in western countries 
(appendix pp 24–27). The excess risks associated with 
daily and with inter mittent progestagen use were 
estimated as being, respectively, about one-sixth greater 
and one-sixth less than this overall excess risk, and the 
excess risks for oestrogen-only MHT were estimated as 
being about one-third as great as it (figure 4).
These absolute risks of developing breast cancer 
during the 20-year age range 50–69 inclusive are shown 
in figure 7. They assume that 6·3% of never users of 
average weight (ie, 6·3 in every 100 never users of MHT) 
would develop breast cancer during this 20-year period 
(appendix pp 17, 18, 24, 25, 26). With 5 years of MHT 
use followed by 15 years of past use, the 20-year risk 
for oestrogen-plus-daily-progestagen would then become 
about 8·3%, an absolute increase of 2·0 per every 100 
women (one in every 50 users). For oestrogen-plus-
intermittent-progestagen, the risk would become about 
7·7%, an absolute increase of 1·4 per 100 women (one in 
every 70 users). For oestrogen-only the risk would 
become about 6·8%, an absolute increase of 0·5 per 100 
women (one in every 200 users; this excess would 
be greater in lean women, but slight in obese women). 
About half the excess would be during the first 5 years of 
current use of MHT, and half would be during the 
next 15 years of past use. The 20-year excess risks with 
10 years of use from age 50 years would be about double 
those with 5 years of use.
Discussion
Users of systemic hormone therapy who started around 
the time of menopause were at greater risk of invasive 
breast cancer than apparently similar never users. Excess 
risks were greater among current than past users, but 
some risk persisted for more than a decade after MHT 
use ceased. There was little excess risk after use of MHT 
for less than 1 year, but there were definite excess risks 
associated with just 1–4 years of use, and progressively 
greater risks with longer use. For a given duration of use, 
the excess risk among current users of MHT was greater 
for ER+ than for ER– disease. The risk was greater for 
oestrogen-progestagen than for oestrogen-only prepar-
ations, particularly if progestagen use was daily rather 
than intermittent. Risks did not differ substantially 
between the main oestrogenic con stituents, or by whether 
oestrogens were administered orally or transdermally. 
There appeared to be little risk, however, from topical 
vaginal oestrogen preparations, which limit systemic 
exposure.10 For the oestrogen-progestagen prep arations, 
risks did not generally differ between different proges-
tagenic constituents, including micronised [natural] 
progesterone, but appeared to be somewhat lower for 
combinations containing dydrogesterone.11
Ovarian function ceases with menopause; thereafter, 
oestrogen levels fall substantially and progesterone levels 
fall to near zero. Endogenous oestrogen synthesis in post-
menopausal women occurs mainly in adipose tissue, 
catalysed by the enzyme aromatase. Postmenopausal 
oestrogen levels therefore correlate strongly with the 
amount of adipose tissue, and hence with BMI,12 and can 
be reduced to nearly zero by treatment with aromatase 
inhibitors.13
Among postmenopausal women in western countries, 
ER+ breast cancer accounts for about three-quarters of all 
breast cancer cases and deaths, and post menopausal 
oestrogenic activity is a strong determinant of the 
incidence of ER+ breast cancer. Among postmenopausal 
Figure 6: Relevance of BMI to the absolute 10 year breast cancer incidence 
rate per 100 women at ages 55–64 years in never users and in current users 
of MHT
Adjusted relative risks for all cancers during 5–14 years of current use were 
calculated taking never users with a BMI of 25–29 kg/m² as the reference, and 
then standardising to the incidence rate of breast cancer in never users aged 
55–64 years of average weight in western countries (ie, 3 per 100 women; 
appendix p 17). Separate results for ER+ and ER– breast cancer are shown (both 
with broken lines) only for never users of MHT (but are shown for current users 
in the appendix, p 48). BMI groups: <25 kg/m² (lean); 25–30 kg/m² 
(overweight); and ≥30 kg/m² (obese); incidence is plotted against mean BMI 
values. BMI=body-mass index. ER+=oestrogen-receptor positive. 
ER–=oestrogen-receptor negative. MHT=menopausal hormone therapy.
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women, the incidence of ER+ breast cancer correlates 
with age at menopause9 and with blood oestrogen levels,12 
and randomised trials have shown that the incidence of 
ER+ breast cancer can be greatly reduced by anti-
oestrogen drugs such as an aromatase inhibitor, or 
tamoxifen. In these trials (appendix p 28), allocation 
to the anti-oestrogen treatment halved the incidence of 
ER+ breast cancer in postmenopausal women during 
the scheduled treatment period (RR 0·51, 99% CI 
0·39–0·65, Z=–6·9, p<10–¹⁰). Hence, among post-
menopausal women oestrogen-only MHT might be 
expected to increase ER+ breast cancer incidence rates, 
as is indicated by the prospective studies.
As postmenopausal adiposity increases endogenous 
oestrogenic activity and increases ER+ breast cancer 
incidence, the magnitude of any effect of MHT on breast 
cancer incidence might be expected to differ by adiposity, 
and it does. BMI is associated with increased incidence of 
ER+ disease in postmenopausal never users of MHT (an 
association that does not weaken with age), but not in 
women who have been using MHT for some years 
(figure 6). Obesity therefore attenuates the absolute and 
the relative excess breast cancer risk associated with 
MHT. Indeed, for women who are obese, use of oestrogen-
only MHT adds little to their already elevated breast 
cancer risk, suggesting that this addition of an exogenous 
oestrogen adds relatively little to the adiposity-associated 
oestrogenic stimulation of their breast tissue. Lean and 
obese women were, however, similar in the absolute 
increase in risk produced by addition of a progestagen (ie, 
in the difference in risk between oestrogen-only MHT 
and oestrogen plus progestagen MHT).  
MHT use is associated with much greater propor tional 
increases in ER+ than ER– disease. Moreover, the excess 
breast cancer risks in MHT users are strongly duration 
dependent. Although MHT users differ in various ways 
from non-users, these biologically plausible findings 
suggest that the excess of ER+ breast cancer associated 
with MHT use, which accounts for most of the overall 
excess of breast cancer associated with MHT use, is 
largely causal (ie, that some years of MHT use, starting at 
around the time of the menopause, increases the 
probability of developing ER+ breast cancer among 
otherwise similar women of the same age). Although it is 
unclear why oestrogen-progestagen preparations would 
have a greater effect than oestrogen-only MHT, there 
Figure 7: Effect of 5 years or of 10 years of MHT use, starting from age 50 years, on 20-year breast cancer incidence rates
Relevance of MHT use and of adiposity to the absolute 20-year risk of developing breast cancer from ages 50–69 years inclusive, assuming that the relative risks found in 
the prospective studies would apply to women of average weight in a typical developed country in which the absolute 20-year risk of developing breast cancer in never 
users is 6·3 per 100 women (appendix pp 17, 18, 24, 25, 26). Results for women of average weight are shown for never users and for various categories of MHT use from 
age 50 years. A) Effects of 5 years or of 10 years of oestrogen-plus-daily-progestagen MHT. B) Effects of 5 years or of 10 years of oestrogen-plus-intermittent-progestagen 
MHT. C) Effects of 5 years or of 10 years of oestrogen-only MHT. D) Effects of adiposity among women who never use MHT, comparing those of average weight with 
those who were lean or obese. MHT=menopausal hormone therapy.
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is no good reason to distrust this statistically reliable 
finding.
There was extensive information in the prospective 
studies on the effects of starting MHT use at various ages 
throughout the range 40–59 years. For women who had 
started anywhere in this age range the RRs among current 
users were similar, and were all highly signifi cant. 
Comparatively few women, however, had started such 
treatment well after the menopause, for example at ages 
60–69 years. Among them, the excess risk was statistically 
definite for oestrogen-progestagen but not for oestrogen-
only preparations, although this non-significant result 
should not be considered in isolation from the highly 
significant excess risks in the younger age groups.
Further evidence about the effects of starting the use of 
such treatments well after the menopause is provided by 
the randomised trials (appendix pp 29, 30), in which the 
main aim was to assess the effects of such treatments 
on vascular disease, which is uncommon before age 
60 years. Much the largest were the two Women’s 
Health Initiative (WHI) trials, one of oestrogen-only, the 
other of oestrogen-progestagen hormonal treatment.14–16 
Both prespecified heart disease as the primary outcome, 
bone fracture as the main secondary outcome, and breast 
cancer as the main potential adverse outcome; their 
original power calculations considered the ability to detect 
a 15–22% increase in breast cancer.14 
In the oestrogen-only trials the average age at 
randomisation was 64 years and the mean between-
group difference in the duration of hormone treatment 
during the scheduled intervention phase but before 
breast cancer onset was about 3·9 years, after allowing 
for non-compliance (appendix p 29). During or after the 
intervention phase a total of 434 women developed breast 
cancer (including 384 in the WHI trial,17 of whom 
327 [85%] were overweight or obese18). The aggregated 
results suggested an unexpected decrease in risk 
(RR 0·77, 99% CI 0·60–0·99, Z=–2·7, p=0·01), possibly 
because starting oestrogen-only therapy well after the 
menopause does not have the same effect on breast 
cancer risk as starting at around the time of the 
menopause.19,20 Another possibility, given the epidemio-
logical evidence that oestrogenic stimulation can 
increase risk and the strong randomised evidence that 
anti-oestrogen drugs can reduce risk in postmenopausal 
women, is that the apparently protective effect of 
hormone treatment in the oestrogen-only trials arose 
mainly by the play of chance, perhaps augmented by 
changes in breast density21–23 somewhat reducing the 
sensitivity of mammographic screening.
In the oestrogen-progestagen trials (appendix p 30) a 
total of 864 women developed breast cancer, including 
757 in the WHI trial,17 and there was no apparent 
discrepancy with the prospective studies.14 Although the 
between-group difference in the duration of hormone 
treatment was only about 3·6 years at cancer diagnosis, 
there was an increase in risk about as great as in the 
WHI power calculations, albeit with wide 99% confidence 
limits (RR 1·26, 99% CI 1·06–1·51; Z=3·4; p=0·0007). 
One limitation of all the available epidemiological 
evidence is that there is still not long enough follow-up 
after cessation of prolonged MHT use by women who 
had started some years of hormonal treatment at around 
the time of menopause. If excess risks in past users are 
real and persist much longer than 15 years, there will be 
some additional hazard after age 70 years. Another 
limitation is that the collaboration sought information 
only on breast cancer incidence, not mortality, and 
incidence can depend on the sensitivity and frequency of 
mammo graphic screening. Breast cancer detection rates 
could have been reduced somewhat by the increase in 
breast density that is caused by hormonal treatment,21–23 
or increased somewhat in populations where screening 
frequency is associated with MHT use, as in the US.24 
The largest prospective study was, however, from the UK, 
where there is a nationwide mammographic screening 
programme. In that study, MHT use was not materially 
associated with screening uptake but was associated with 
an increase not only in breast cancer incidence (of similar 
magnitude to that in all prospective studies; appendix 
p 34) but also in 20-year breast cancer mortality. This 
increase in breast cancer mortality was greater for 
oestrogen-progestagen than for oestrogen-only prepar-
ations; of the fatal breast cancers, three-quarters with 
known receptor status were ER+.25
Cases continue to accrue in the prospective studies, 
but there is no good reason to expect further follow-up 
would materially alter the main findings for current 
users. To limit biases, the main analyses were restricted 
to prospective studies, allowed for early menopause 
decreasing breast cancer risk and bringing forward the 
age when MHT is started, and adjusted for various other 
potential confounding factors (as other correlates of 
breast cancer risk might also affect the type or timing of 
MHT use). Current users were included up to no more 
than 5 years after their last reported MHT use; among 
them there were, on average, only 1·4 years between the 
last report about their MHT use and their index date. 
Some additional use must have occurred during that 
period, as must some discontinuation, but both have 
been allowed for (although RRs in current users must 
still have been slightly weakened by discontinuation 
before the index date). With all these safeguards, the 
findings are trustworthy for the main patterns of use in 
the prospective studies.
The clinical relevance of the main findings lies in the 
magnitude of the absolute risks during and after MHT 
use for women who start MHT at ages 40–59 years 
(figure 7; appendix pp 24–27), but the public health 
relevance depends additionally on the numbers of 
women previously and currently exposed. Although use 
of either type of MHT for less than 1 year was associated 
with little subsequent risk, for women of average 
weight in developed countries 5 years of use, starting 
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at age 50 years, would cause an appreciable increase 
in the probability of developing breast cancer at ages 
50–69 years. About half the excess would be during the 
first 5 years of current use of MHT, and half would be 
during the next 15 years of past use. The absolute 
increase would be about 2·0 per 100 women (one in 
every 50 users) for oestrogen-plus-daily-progestagen 
MHT, 1·4 per 10 women (one in 70 users) for oestrogen-
plus-intermittent-progestagen MHT, and 0·5 per 100 
women (one in 200 users) for oestrogen-only MHT. 
There is little difference in the absolute excess incidence 
by age 70 associated with starting 5 years of MHT use at 
ages 45 years, 50 years, or 55 years. Thus, addition of a 
daily progestagen increases the excess risk of breast 
cancer from one in 200 users to one in 50 users.
The corresponding risks with 10 years of use starting at 
age 50 years would be about twice as great. In western 
countries there have been about 20 million breast cancers 
diagnosed since 1990, of which about 1 million would have 
been caused by MHT use.
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